CliffBio
biologic

Rybrevant Faspro

amivantamab and hyaluronidase-lpuj

Loss of exclusivityFebruary 2038projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →View the full company profile on CliffBio

Drug detail

Brand nameRybrevant Faspro
Active ingredientamivantamab and hyaluronidase-lpuj
Strength2,240MG/14ML; 28,000UNITS/14ML (160MG/2,000UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalFebruary 2026
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rybrevant Faspro patent cliff — loss of exclusivity February 2038 | CliffBio